Your Health

Health Day - ONLINE EDITION

Zytiga's Use Expanded for Advanced Prostate Cancer

Decreases body's production of testosterone

By: Staff Writer

Posted: 12/10/2012 5:00 PM | Comments: 0

MONDAY, Dec. 10 (HealthDay News) -- U.S. Food and Drug Administration approval of Zytiga (abiraterone acetate) has been expanded to include treating late-stage castration-resistant prostate cancer before the administration of chemotherapy, the agency said Monday.

The drug, designed to decrease production of the male sex hormone testosterone, was first approved in November 2011. Testosterone is thought to spur the growth of prostate tumors, the FDA said in a news release.

Zytiga's approval for the new use followed a clinical study of 1,088 men with advanced, castration-resistant prostate cancer who hadn't received chemotherapy. Men who took Zytiga had a median survival of 35.3 months, compared to 30.1 months among those who took a placebo.

The most common adverse reactions included fatigue, swollen joints, hot flushes, diarrhea, vomiting, cough and high blood pressure.

Zytiga is marketed by Janssen Biotech, based in Horsham, Penn.

More information

To learn more about prostate cancer, visit the U.S. Centers for Disease Control and Prevention.

Fact Check

Have you found an error, or know of something we’ve missed in one of our stories? Please use the form below and let us know.

* Required

In which story did you find the error? *
Please post the headline of the story or the title of the video with the error.
What was the error? *
Please post exactly what was wrong with the story.
What should we have written?
Please indicate your source for the correct information.
Who else should we interview to improve this story?
Please include any contact information you may have.
Can we contact you in the future for advice on stories about this topic?
Yes

No
First Name: *
Last Name: *
E–mail Address: *
This will only be used to contact you if we have a question about your submission, it will not be used to identify you or be published.
Phone: *
This will only be used to contact you if we have a question about your submission, it will not be used to identify you or be published.
Colour:
Are you blue? If you can see this, leave it blank and get some CSS support.
Enter the words that you see: * This is to prevent our forms from being filled out automatically.
You have failed to correctly identify the words in the box above. Please try again.

More Your Health

Undock

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is register and/or login and you can join the conversation and give your feedback.

Have Your Say

New to commenting? Check out our Frequently Asked Questions.

The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.